IL-33 Isoforms: Their Future As Vaccine Adjuvants?

Overview

Journal Expert Rev Vaccines

Date 2015 Feb 7

PMID 25656504

Citations 10

Authors

Daniel O Villarreal

David B Weiner

Affiliations

Soon will be listed here.

Abstract

The identification and characterization of cytokine isoforms is likely to provide critical important new insight into immunobiology. Cytokine isoforms can provide additional diversity to their complex biological effects that participate in control and protection against different foreign pathogens. Recently, IL-33 has been identified as a proinflammatory cytokine having several different biologically active isoform products. Originally associated with Th2 immunity, new evidence now supports the role of two IL-33 isoforms to facilitate the generation of protective Th1 and CD8 T cell immunity against specific pathogens. Therefore, a better understanding of the IL-33 isoforms will inform us on how to utilize them to facilitate their development as tools as vaccine adjuvants for immune therapy.

Citing Articles

Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.

Andreone S, Gambardella A, Mancini J, Loffredo S, Marcella S, La Sorsa V Front Immunol. 2020; 11:571593.

PMID: 33329534 PMC: 7734277. DOI: 10.3389/fimmu.2020.571593.

IL-33 Alarmin and Its Active Proinflammatory Fragments Are Released in Small Intestine in Celiac Disease.

Perez F, Ruera C, Miculan E, Carasi P, Dubois-Camacho K, Garbi L Front Immunol. 2020; 11:581445.

PMID: 33133101 PMC: 7578377. DOI: 10.3389/fimmu.2020.581445.

The ambient ozone and COVID-19 transmissibility in China: A data-driven ecological study of 154 cities.

Ran J, Zhao S, Han L, Chen D, Yang Z, Yang L J Infect. 2020; 81(3):e9-e11.

PMID: 32652165 PMC: 7342057. DOI: 10.1016/j.jinf.2020.07.011.

Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Challenge in a Mouse Model.

Reeder S, Reuschel E, Bah M, Yun K, Tursi N, Kim K Vaccines (Basel). 2020; 8(1).

PMID: 31936739 PMC: 7157753. DOI: 10.3390/vaccines8010021.

The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Afferni C, Buccione C, Andreone S, Galdiero M, Varricchi G, Marone G Front Immunol. 2018; 9:2601.

PMID: 30483263 PMC: 6242976. DOI: 10.3389/fimmu.2018.02601.

References

Le H, Kim W, Kim J, Cho H, Kwon B . Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front Immunol. 2013; 4:104. PMC: 3644799. DOI: 10.3389/fimmu.2013.00104. View

Wang L, Li H, Liang F, Hong Y, Jiang S, Xiao L . Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-γ. Med Oncol. 2014; 31(9):143. DOI: 10.1007/s12032-014-0143-0. View

Martin M . Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol. 2013; 25(6):449-57. DOI: 10.1016/j.smim.2013.10.006. View

Vudattu N, Magalhaes I, Hoehn H, Pan D, Maeurer M . Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun. 2008; 10(2):132-40. DOI: 10.1038/gene.2008.90. View

Luzina I, Pickering E, Kopach P, Kang P, Lockatell V, Todd N . Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol. 2012; 189(1):403-10. PMC: 3381874. DOI: 10.4049/jimmunol.1200259. View

Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N . Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008; 20(6):791-800. DOI: 10.1093/intimm/dxn037. View

Tsuda H, Komine M, Karakawa M, Etoh T, Tominaga S, Ohtsuki M . Novel splice variants of IL-33: differential expression in normal and transformed cells. J Invest Dermatol. 2012; 132(11):2661-4. DOI: 10.1038/jid.2012.180. View

Commins S, Borish L, Steinke J . Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2009; 125(2 Suppl 2):S53-72. DOI: 10.1016/j.jaci.2009.07.008. View

Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N . IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012; 52(1-2):89-99. DOI: 10.1007/s12026-012-8283-9. View

10.

Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J . IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A. 2012; 109(5):1673-8. PMC: 3277172. DOI: 10.1073/pnas.1115884109. View

11.

Villarreal D, Wise M, Walters J, Reuschel E, Choi M, Obeng-Adjei N . Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014; 74(6):1789-800. PMC: 4130175. DOI: 10.1158/0008-5472.CAN-13-2729. View

12.

Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert E . The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513(7519):564-568. PMC: 4339042. DOI: 10.1038/nature13577. View

13.

Ngoi S, St Rose M, Menoret A, Smith D, Tovey M, Adler A . Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A. 2012; 109(26):10486-91. PMC: 3387033. DOI: 10.1073/pnas.1202607109. View

14.

Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T . Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem. 2011; 286(22):20078-86. PMC: 3103380. DOI: 10.1074/jbc.M111.219089. View

15.

Price A, Liang H, Sullivan B, Reinhardt R, Eisley C, Erle D . Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A. 2010; 107(25):11489-94. PMC: 2895098. DOI: 10.1073/pnas.1003988107. View

16.

Whitaker E, Filippov V, Filippova M, Guerrero-Juarez C, Duerksen-Hughes P . Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells. Cytokine. 2011; 56(2):272-81. PMC: 3185131. DOI: 10.1016/j.cyto.2011.07.020. View

17.

Bonilla W, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S . The alarmin interleukin-33 drives protective antiviral CD8⁺ T cell responses. Science. 2012; 335(6071):984-9. DOI: 10.1126/science.1215418. View

18.

Garcia-Blanco M . Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest. 2003; 112(4):474-80. PMC: 171395. DOI: 10.1172/JCI19462. View

19.

Villarreal D, Weiner D . Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol. 2014; 28:102-6. PMC: 4118594. DOI: 10.1016/j.coi.2014.03.004. View

20.

Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I . Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology. 2014; 3:e29030. PMC: 4091551. DOI: 10.4161/onci.29030. View